Canada High Court delivers good news to patent owners (full version)
10 November 2008
Eileen McDermott, New York
The Supreme Court of Canada has clarified the tests for anticipation and obviousness and reaffirmed the patentability of so-called selection patents in a ruling that could amount to a major boon for Canadian pharmaceutical companies, as well as patentees in general
The judgment , authored by Justice Marshall Rothstein, upheld Canadian pharmaceutical company Sanofi-Aventis's patent for Plavix (clopidogrel bisulfate), a popular blood clot inhibitor, rejecting generic drug company Apotex's claims that the patent was invalid for anticipation, obviousness and double patenting.
In 2003, Apotex served a Notice of Allegation on Sanofi-Aventis to obtain a Notice of Compliance from the Minister of Health to market its generic version of Plavix before Sanofi's patent had expired.
Apotex claimed that the Plavix patent was invalid on the grounds of anticipation, obviousness and double patenting, since the compound on which the patent was based had been disclosed in an earlier patent, also owned by Sanofi-Aventis.
Sanofi-Aventis successfully blocked the issuance of the Notice of Compliance and the Federal Court of Appeal upheld the decision. The Supreme Court agreed to hear Apotex's appeal, and on Thursday it upheld the Plavix patent.
The ruling is significant since it...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial